MAP — Microba Life Sciences Share Price
Last trade - 00:00- AU$80.61m
- AU$53.94m
- AU$5.42m
- 30
- 22
- 41
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.64 | ||
| Price to Tang. Book | 2.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.42% | ||
| Return on Equity | -39.09% | ||
| Operating Margin | -386.72% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.83 | 2.91 | 3.73 | 4.69 | 5.42 | 11.82 | 19.69 | 31.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Microba Life Sciences Limited is an Australia-based precision microbiome company. The Company is engaged in the discovery and development of therapeutics for major chronic diseases and delivers gut microbiome testing services globally to researchers, clinicians, and consumers. It offers various platforms, such as Analysis, Discovery, and Therapeutic. Through its analysis and discovery platforms, it identifies microbiome-derived therapeutics and diagnostic tools to advance medicine. Through its Analysis Platform, it generates a global databank of microbiome samples and associated metadata to develop new health solutions. Its Discovery Platform enables partners to access this databank for the data-driven discovery of product opportunities. Its therapeutic platform is a repeatable platform for microbial therapeutic leads. It also offers a product portfolio of gastrointestinal, vaginal, oral, and urinary microbiome testing, together with a targeted set of evidence-based formulations.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 31st, 2017
- Public Since
- April 5th, 2022
- No. of Shareholders
- 1,189
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 447,851,977
- Address
- 324 Queen Street, Level 10, BRISBANE, 4000
- Web
- https://www.microba.com/
- Phone
- +61 732228444
- Auditors
- Pitcher Partners
Upcoming Events for MAP
Similar to MAP
Apiam Animal Health
Australian Stock Exchange - SEATS
Artrya
Australian Stock Exchange - SEATS
Australian Clinical Labs
Australian Stock Exchange - SEATS
Cann
Australian Stock Exchange - SEATS
Capitol Health
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:14 UTC, shares in Microba Life Sciences are trading at AU$0.18. This share price information is delayed by 15 minutes.
Shares in Microba Life Sciences last closed at AU$0.18 and the price had moved by -38.98% over the past 365 days. In terms of relative price strength the Microba Life Sciences share price has underperformed the ASX All Ordinaries Index by -42.48% over the past year.
The overall consensus recommendation for Microba Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Microba Life Sciences does not currently pay a dividend.
Microba Life Sciences does not currently pay a dividend.
Microba Life Sciences does not currently pay a dividend.
To buy shares in Microba Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.18, shares in Microba Life Sciences had a market capitalisation of AU$80.61m.
Here are the trading details for Microba Life Sciences:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MAP
Based on an overall assessment of its quality, value and momentum Microba Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Microba Life Sciences is AU$0.38. That is 111.11% above the last closing price of AU$0.18.
Analysts covering Microba Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.04 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Microba Life Sciences. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -31.37%.
As of the last closing price of AU$0.18, shares in Microba Life Sciences were trading -28.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Microba Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Microba Life Sciences' directors